A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib

14847NOVARTISCLOU064C12302OpenA randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib CLOU064C12302 NCT05156281IndustrialAdultTreatmentOtherAmjad, FariaGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Neurology; GUMC PFS2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>